



## Novel Targets in Triple-Negative Breast Cancer

Guest Editors:

### **Prof. Alberto Ocaña**

Centro Regional de  
Investigaciones Biomédicas  
(CRIB), Castilla La Mancha  
University, Albacete, Spain

### **Dr. Atanasio Pandiella**

Centro de Investigación del  
Cáncer (Universidad de  
Salamanca-CSIC), Campus  
Universitario Miguel de Unamuno  
s/n, 37007 Salamanca, Spain

Deadline for manuscript  
submissions:

**closed (31 August 2021)**

### **Message from the Guest Editors**

Dear Colleagues,

Although there have been several advances in the treatment of breast cancer, for the triple-negative subtype very limited therapeutic options exist. In this breast cancer group checkpoint and PARP inhibitors have been recently incorporated into our clinical armamentarium, but there are still several challenges, such as the stratification of patients based on the right biomarkers. This Special Issue will collect a series of articles that provide new information about the current stage of novel therapeutic efforts in this indication. We will combine “up-to-date” reviews with original articles that report novel findings. We kindly encourage researchers and physician-scientists to submit their work to this Special Issue.

Prof. Alberto Ocaña

Dr. Atanasio Pandiella

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)